These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17097981)

  • 1. Scarce influence of corticosteroid boluses on long-term viral load and liver histology in transplanted patients with recurrent hepatitis C.
    Barcena R; Oton E; Barreales M; Castillo M; Blesa C
    Transplant Proc; 2006 Oct; 38(8):2502-4. PubMed ID: 17097981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus recurrence after liver transplantation: influence of immunosuppressive regimens on viral load and liver histology.
    Oton E; Barcena R; Castillo M; Barreales M; Blesa C; Moreno-Planas JM; Barrios C; Garrido A; Cuervas V
    Transplant Proc; 2006 Oct; 38(8):2499-501. PubMed ID: 17097980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.
    Testillano M; Fernandez JR; Suarez MJ; Gastaca M; Bustamante J; Pijoan JI; Montejo M; Valdivieso A; Ruiz P; Gonzalez J; Ortiz de Urbina J
    Transplant Proc; 2009 Apr; 41(3):1041-3. PubMed ID: 19376421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel immunosuppressive strategy combined with preemptive antiviral therapy improves the eighteen-month mortality in HCV recipients transplanted with aged livers.
    Urbani L; Mazzoni A; Colombatto P; Bindi L; Biancofiore G; Tascini C; Menichetti F; Brunetto MR; Scatena F; Filipponi F
    Transplantation; 2008 Dec; 86(12):1666-71. PubMed ID: 19104402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation.
    Chopra KB; Demetris AJ; Blakolmer K; Dvorchik I; Laskus T; Wang LF; Araya VR; Dodson F; Fung JJ; Rakela J; Vargas HE
    Transplantation; 2003 Nov; 76(10):1487-91. PubMed ID: 14657691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss.
    Bahra M; Neumann UP; Jacob D; Langrehr JM; Neuhaus P
    Transplant Proc; 2005 May; 37(4):1700-2. PubMed ID: 15919436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.
    Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
    J Hepatol; 2006 Apr; 44(4):717-22. PubMed ID: 16487616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis.
    Samonakis DN; Mela M; Quaglia A; Triantos CK; Thalheimer U; Leandro G; Pesci A; Raimondo ML; Dhillon AP; Rolles K; Davidson BR; Patch DW; Burroughs AK
    Transpl Infect Dis; 2006 Mar; 8(1):3-12. PubMed ID: 16623815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid-free immunosuppression after liver transplantation does not increase the risk of graft fibrosis.
    Manzia TM; Toti L; Angelico R; Di Cocco P; Orlando G; Tisone G
    Transplant Proc; 2010 May; 42(4):1237-9. PubMed ID: 20534270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: impact on recurrent hepatitis C virus infection.
    Nair S; Loss GE; Cohen AJ; Eason JD
    Transplantation; 2006 Feb; 81(4):620-2. PubMed ID: 16495812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection.
    Neff GW; O'Brien CB; Nery J; Shire NJ; Nishida S; delaGarza J; Montalbano M; Safdar K; Ruiz P; Rideman E; Gascon JA; Tzakis AG; Madariaga J; Rudich SM
    Liver Transpl; 2004 Dec; 10(12):1497-503. PubMed ID: 15558835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation.
    Yilmaz N; Shiffman ML; Stravitz RT; Sterling RK; Luketic VA; Sanyal AJ; Mills AS; Contos MJ; Coterell A; Maluf D; Posner MP; Fisher RA
    Liver Transpl; 2007 Jul; 13(7):975-83. PubMed ID: 17600360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation.
    Shackel NA; Jamias J; Rahman W; Prakoso E; Strasser SI; Koorey DJ; Crawford MD; Verran DJ; Gallagher J; McCaughan GW
    Liver Transpl; 2009 Jul; 15(7):709-18. PubMed ID: 19562704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus viral load after conversion from tacrolimus to cyclosporine in liver transplant patients: a pilot study.
    Guitard J; Sandres-Sauné K; Kamar N; Ribes D; Faguer S; Esposito L; Lavit M; Muscari F; Péron JM; Lavayssière L; Durand D; Rostaing L
    Transplant Proc; 2007 Oct; 39(8):2603-5. PubMed ID: 17954189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spontaneous clearance of HCV in HIV-hepatitis C virus coinfected liver transplant patients: prospective study.
    Gutiérrez-Moreno M; Bernal-Bellido C; Suárez-Artacho G; Alamo-Martínez JM; Marín-Gómez LM; Serrano-Díaz-Canedo J; Padillo-Ruiz FJ; Gómez-Bravo MA
    Transplant Proc; 2012 Sep; 44(7):2100-2. PubMed ID: 22974923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C.
    Margarit C; Bilbao I; Castells L; Lopez I; Pou L; Allende E; Escartin A
    Transpl Int; 2005 Dec; 18(12):1336-45. PubMed ID: 16297052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.
    Fernández I; Ulloa E; Colina F; Abradelo M; Jiménez C; Gimeno A; Meneu JC; Lumbreras C; Solís-Herruzo JA; Moreno E
    Liver Transpl; 2009 Aug; 15(8):948-55. PubMed ID: 19642125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of clinical parameters when differentiating cholestatic hepatitis C virus from allograft rejection.
    Neff GW; Shire N; Ruiz P; O'Brien C; Garcia M; Dela Garza J; Rudich SR; Reddy KR
    Transplant Proc; 2005 Dec; 37(10):4397-402. PubMed ID: 16387130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective analysis of the impact of immunosuppression on the course of recurrent hepatitis C after liver transplantation.
    Bahr MJ; Beckermann JG; Rifai K; Gehrmann L; Rosenau J; Klempnauer J; Strassburg CP; Manns MP
    Transplant Proc; 2005 May; 37(4):1703-4. PubMed ID: 15919437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus sensitivity to combined antiviral therapy in liver transplant versus immunocompetent patients.
    Redondo I; Otón E; Bárcena R; Del Campo S; Rodriguez-Gandía M; Cuervas-Mons V
    Transplant Proc; 2009; 41(6):2195-6. PubMed ID: 19715871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.